Back to search

Article

CRISPR-Cas9 Therapeutics in Diabetes Mellitus: From Molecular Mechanisms and Pharmacology to Clinical Development and Translational Barriers

2026-06-22

Abstract excerpt

Diabetes mellitus represents a growing global health burden driven by complex and incompletely understood molecular pathology, for which existing pharmacological strategies provide metabolic control without addressing the underlying biological defects. CRISPR-Cas9 genome editing has emerged as a transformative precision medicine platform with the potential to move beyond symptomatic management toward durable, mech...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a271b219-b3a0-5f53-a398-e6a7e2fee234
DOI
10.22541/authorea.15004994/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CRISPR-Cas9 Therapeutics in Diabetes Mellitus: From Molecular Mechanisms and Pharmacology to Clinical Development and Translational BarriersDOI 10.22541/authorea.15004994/v1
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”Semantic proximity
CRISPR-based genome editing in primary human pancreatic islet cellsSemantic proximity
Current therapies and targets for type 2 diabetes mellitusSemantic proximity
Genome-edited human stem cell-derived beta cells: a powerful tool for drilling down on type 2 diabetes GWAS biologySemantic proximity
Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes ResearchSemantic proximity
A genome-wide CRISPR screen identifies regulators of beta cell function involved in type 2 diabetes riskSemantic proximity
Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoproteinSemantic proximity
Applications of Genome-Editing Technologies for Type 1 DiabetesSemantic proximity
Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoproteinSemantic proximity
Genome editing of human pancreatic beta cell models: problems, possibilities and outlookSemantic proximity
CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?Semantic proximity
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes riskSemantic proximity
Select a neighboring publication to make it the new centre.